Bogue Zachary
Insider CIK 1836157 · RXRX Director, 10% owner · ABCL 10% owner · EMBK 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-07-03 | 2023-07-06 | 1,440 | — | $0 | 9,378 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-04-03 | 2023-04-05 | 1,542 | — | $0 | 7,938 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-01-03 | 2023-01-05 | 1,407 | — | $0 | 6,396 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-10-03 | 2022-10-05 | 977 | — | $0 | 4,989 | SEC↗ |
| EMBK Embark Technology, Inc. | P Buy | 2022-08-30 | 2022-09-01 | 10,000 | $9.64 | $96.4K | 3,212,107 | SEC↗ |
| EMBK Embark Technology, Inc. | P Buy | 2022-08-18 | 2022-08-22 | 10,000 | $11.64 | $116.4K | 3,202,107 | SEC↗ |
| EMBK Embark Technology, Inc. | P Buy | 2022-08-16 | 2022-08-18 | 122,000 | $0.84 | $102.5K | 3,192,107 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-07-01 | 2022-07-06 | 1,260 | — | $0 | 4,012 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-04-01 | 2022-04-05 | 1,382 | — | $0 | 2,752 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-01-03 | 2022-01-05 | 589 | — | $0 | 1,370 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2021-10-01 | 2021-10-05 | 295 | — | $0 | 781 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2021-07-01 | 2021-07-06 | 295 | — | $0 | 295 | SEC↗ |
| ABCL AbCellera Biologics Inc. | J Other | 2021-06-18 | 2021-06-22 | 73,892 | — | $0 | 73,892 | SEC↗ |
| ABCL AbCellera Biologics Inc. | J Other | 2021-06-18 | 2021-06-22 | 5,000,000 | — | $0 | 24,105,761 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 1,095,529 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 730,353 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 3,726,963 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 3,220,788 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 1,073,595 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 3,771,996 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion | 2021-04-20 | 2021-04-22 | 5,941,120 | — | $0 | 5,941,120 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 5,941,120 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 5,941,120 | — | $0 | 5,941,120 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion | 2021-04-20 | 2021-04-22 | 3,951,141 | — | $0 | 3,951,141 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 3,951,141 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 3,951,141 | — | $0 | 3,951,141 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion | 2021-04-20 | 2021-04-22 | 3,726,963 | — | $0 | 3,726,963 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 3,726,963 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 3,726,963 | — | $0 | 3,726,963 | SEC↗ |
| ABCL AbCellera Biologics Inc. | C Conversion deriv | 2020-12-15 | 2020-12-17 | 2,105,264 | — | $0 | 0 | SEC↗ |
| ABCL AbCellera Biologics Inc. | C Conversion deriv | 2020-12-15 | 2020-12-17 | 802,371 | — | $0 | 0 | SEC↗ |
| ABCL AbCellera Biologics Inc. | C Conversion deriv | 2020-12-15 | 2020-12-17 | 0 | — | $0 | 0 | SEC↗ |
| ABCL AbCellera Biologics Inc. | C Conversion | 2020-12-15 | 2020-12-17 | 29,411 | — | $0 | 29,105,761 | SEC↗ |
| ABCL AbCellera Biologics Inc. | C Conversion | 2020-12-15 | 2020-12-17 | 29,076,350 | — | $0 | 29,076,350 | SEC↗ |